Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECT 3
2021-003951-41Phase 4Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in asthma comparing Budesonide/Formoterol Digihaler Digital System with Standard of Care (2 arms). Primary endpoint: Asthma control responder rate at Week 24. Started Dec 2022; status: terminated.
02
Drugs
Digihalerbudesonideformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2021-003951-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003951-41.